Chronic hepatitis C virus in the State of Piauí, Northeastern Brazil

Brazilian Journal of Infectious Diseases

Volumn 13, Issue 2, 2009, Pages 125-129

  Veras, Kelson Nobre ^a   Jacobina, Kelson Sousa ^a   Soares, Vítor Y Rocha ^a   Avelino, Marcela Amaral ^a   Vasconcelos, Conceição De Maria S R ^a   Parenter, José Miguel L ^a  

^a FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

Author keywords

Chronic hepatitis C; Epidemiology; Genotype distribution; Hepatitis C virus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAZIL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; TREATMENT INDICATION; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; BRAZIL; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VIRAL LOAD; YOUNG ADULT;

EID: 76649123969     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1413-86702009000200011     Document Type: Article

References (34)

1. Robertson B., Myers G., Howard C., et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. Arch Virol 1998;143:2493-2503.
2. Simmonds P., Holmes E.C., Cha T.A., et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391-9.
3. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
4. Poynard T., Marcellin P., Lee S.S., et al. Randomized trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.
5. Manns M.P., McHutchison J.G., Gordon S.C., et al. PEG-interferon alfa-2b in combination with ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65.
6. Fried M., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
7. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002;36(5B):21-9.
8. Smuts H.E., Kannemeyer J. Genotyping of hepatitis C virus in South Africa. J Clin Microbiol 1995;33:1679-81.
9. Songsivilai S., Kanistanon D., Dharakul T. A serotyping assay for hepatitis C virus in Southeast Asia. Clin Diagn Lab Immunol 1998;5:737-9.
10. Zein N.N. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000;13:223-35.
11. Focaccia R., Baraldo D.C.M., Ferraz M.L.G., et al. Demographic and anthropometrical analysis and genotype distribution of chronic hepatitis C patients treated in public and private reference centers in Brazil. Braz J Infect Dis 2004;8(5):348-55.
12. Parana R., Vitvitski L., Berby F., et al. HCV infection in northeastern Brazil: unexpected high prevalence of genotype 3a and absence of African genotypes. Arq Gastroenterol 2000;37(4):213-6.
13. Codes L., Freitas L.A.R., De Santos-Jesus R., et al. Comparative study of Hepatitis C virus genotypes 1 and 3 in Salvador, Bahia. Braz J Infect Dis 2003;7(6):409-17.
14. Silva L.K., Parana R., Souza S.P., et al. Hepatitis C virus genotypes in a Northeastern area of Brazil. Am J Trop Med Hyg 2000;62:257-60.
15. Oliveira M.L.A., Bastos F.I., Sabino R.R., et al. Distribution of HCV genotypes among different exposure categories in Brazil. Braz J Med Biol Res 1999;32(3):279-82.
16. Martins R.M.B., Vanderborght B.O.M., Yoshida C.F.T. Hepatitis C virus genotypes among blood donors from different regions of Brazil. Mem Inst Oswaldo Cruz 1998;93(3):299-300.
17. Silva G.F., Nishimura N.F., Coelho K.I.R., et al. Grading and staging chronic hepatitis C and its relation to genotypes and epidemiological factors in Brazilian blood donors. Braz J Infect Dis 2005;9(2):142-9.
18. Oliveira G.C., Carmo R.A., Rocha M.O.C., et al. Hepatitis C virus genotypes in hemophiliacs in the state of Minas Gerais, Brazil. Transfusion 1999;39(11):1194-9.
19. Carmo R.A., Oliveira G.C., Guimarães M.D.C., et al. Hepatitis C virus infection among Brazilian hemophiliacs: a virological, clinical and epidemiological study. Braz J Med Biol Res 2002;35(5):589-98.
20. Carneiro M.A.S., Martins R.M.B., Teles S.A., et al. Hepatitis C prevalence and risk factors in hemodialysis patients in Central Brazil: a survey by polymerase chain reaction and serological methods. Mem Inst Oswaldo Cruz 2001;96(6):765-9.
21. Busek S.U., Babá E.H., Tavares Filho H.A., et al. Hepatitis C and hepatitis B virus infection in different hemodialysis units in Belo Horizonte, Minas Gerais, Brazil. Mem Inst Oswaldo Cruz 2002;97(6):775-8.
22. Gayotto L.C.C. e Comitê SBP/SBH. Visão histórica e consenso nacional sobre a classificação das hepatites crônicas. GED 2000;19:137-40.
23. Vasconcelos C.M.S.R., Monte S.J.H., Yoshida C.F.T. Prevalência do anticorpo para o vírus da hepatite C e distribuição do seu genótipo em doadores voluntários de sangue e em pacientes submetidos à hemodiálise em Teresina, Piauí. 2001, 90 pág. Dissertação de Mestrado. UFPI. Teresina.
24. Bassit L., Da Silva L.C., Ribeiro-dos-Santos, G., et al. Chronic hepatitis C virus infections in Brazilian patients: association with genotypes, clinical parameters and response to long term alpha interferon therapy. Rev Inst Med Trop S Paulo 1999;41(3):183-9.
25. Alves A.V., Azevedo A.P.C., Perin C., et al. Tratamento de pacientes com hepatite crônica pelo vírus C com interferon-alfa e ribavirina: a experiência da Secretaria de Saúde do Rio Grande do Sul. Arq Gastroenterol 2003;40(4):227-32.
26. Bourlière M., Barberin J.M., Rotily M., et al. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat 2000; 9(1):62-70.
27. Parana R., Lyra L., Trepo C. Intravenous vitamin complexes used in sporting activities and transmission of HCV in Brazil. Am J Gastroenterol 1999;94(3):857-858.
28. Araújo E.S.A., Cavalheiro N.P., Leitão R.M.C., et al. Hepatitis C viral load does not predict disease outcome: going beyond numbers. Rev Inst Med Trop S Paulo 2002;44(2):71-8.
29. Shakil A.O., Conry-Cantilena C., Alter H.J., et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995;7:123:330.
30. Giannini E., Botta F., Fasoli A., et al. Increased levels of γGT suggest the presence of bile duct lesions in patients with chronic hepatitis C. Dig Dis Sci 2001;46(3):524-9.
31. Pratt D.S., Kaplan M.M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266-71.
32. Conigrave K.M., Degenhardt L.J., Whitfield J.B., et al. On behalf of the WHO/ISBRA Study Group. CDT, GGT, and AST as markers of alcohol use: The WHO/ISBRA Collaborative Project. Alcohol Clin Exp Res 2002;26(3):332-9.
33. Strader D.B., Wright T., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39(4):1147-71.
34. Zarife M.A.S., Silva L.K., Silva M.B.S., et al. Prevalence of hepatitis C virus infection in northeastern Brazil: a population-based study. Trans R Soc Trop Med Hyg 2006;100:663-8.